https://www.bio-focus.co.uk/pharma/pharma-%26-biotech-quality-summit-2026 2026-04-10 https://www.bio-focus.co.uk/pharma/proimmune-and-roslin-institute-partner-to-expand-tools-for-veterinary-immunology 2026-03-22 https://www.bio-focus.co.uk/pharma/nxera-pharma%3A-building-a-next-generation-biopharma-through-technology-and-global-reach 2026-03-20 https://www.bio-focus.co.uk/pharma/belite-bio-reports-breakthrough-phase-3-results-for-potential-stargardt-disease-treatment 2025-12-02 https://www.bio-focus.co.uk/pharma/study-shows-tremfya%C2%AE-slows-psoriatic-arthritis-progression-at-48-weeks 2025-11-17 https://www.bio-focus.co.uk/pharma/world-first-preventative-lung-cancer-vaccine-enters-clinical-trial 2025-11-17 https://www.bio-focus.co.uk/pharma/optibrium-launches-stardrop-8%2C-bringing-real-time-collaboration-to-molecular-design 2025-11-05 https://www.bio-focus.co.uk/pharma/astellas-reports-long-term-benefits-and-strong-safety-profile-for-izervay%E2%84%A2-in-geographic-atrophy 2025-10-21 https://www.bio-focus.co.uk/pharma/novo-nordisk-pulls-plug-on-cell-therapy-in-%241.3b-restructuring-push 2025-10-12 https://www.bio-focus.co.uk/pharma/closed-loop-medicine-brings-personalized-glp-1-dosing-to-the-u.s-with-wedosify 2025-09-20 https://www.bio-focus.co.uk/pharma/vedanta-biosciences-announces-phase-2-results-for-ve202-in-ulcerative-colitis%2C-strengthens-focus-on-lead-program-ve303 2025-09-02 https://www.bio-focus.co.uk/pharma/eli-lilly's-oral-glp-1-candidate-orforglipron-shows-12%25-weight-loss-in-pivotal-trial%2C-eyes-regulatory-filing 2025-08-10 https://www.bio-focus.co.uk/pharma/antibodies.com-supercharges-uk-operations-with-move-to-larger-cambridge-hq 2025-08-04 https://www.bio-focus.co.uk/pharma/compass-pathways'-phase-3-psilocybin-readout-raises-efficacy-questions-despite-meeting-primary-endpoint 2025-06-23 https://www.bio-focus.co.uk/pharma/novo-nordisk-strikes-%24812-million-deal-with-deep-apple-therapeutics-to-strengthen-obesity-pipeline 2025-06-11 https://www.bio-focus.co.uk/pharma/eli-lilly's-kisunla-(donanemab)-receives-marketing-authorization-in-great-britain-for-early-alzheimer's-disease-treatment 2025-06-02 https://www.bio-focus.co.uk/pharma/breakthrough-%22armoured%22- 2025-07-06 https://www.bio-focus.co.uk/pharma/women%E2%80%99s-health-therapeutics-market-enters-transformative-growth-phase 2025-05-19 https://www.bio-focus.co.uk/pharma/uk-us-trade-deal%3A-what's-in-it-for-pharma%3F 2025-05-19 https://www.bio-focus.co.uk/pharma/vyne-therapeutics-faces-clinical-hold-on-vyn202-program-following-toxicity-findings 2025-05-10 https://www.bio-focus.co.uk/pharma/ascletis-sharpens-glp-1-strategy-following-positive-phase-1b-data-for-oral-asc30 2025-04-27 https://www.bio-focus.co.uk/pharma/pfizer-halts-development-of-oral-glp-1-agonist-danuglipron-amid-liver-safety-signal 2025-04-14 https://www.bio-focus.co.uk/pharma/the-current-and-future-state-of-personalised-medicine 2025-04-08 https://www.bio-focus.co.uk/pharma/novo-nordisk-announces-promising-results-for-cagrisema-but-stocks-tell-different-story 2025-03-10 https://www.bio-focus.co.uk/pharma/jazz-pharmaceuticals-to-acquire-chimerix%2C-enhancing-oncology-portfolio 2025-03-10 https://www.bio-focus.co.uk/pharma/weighing-the-costs-of-semaglutide 2025-09-29 https://www.bio-focus.co.uk/pharma/pfizer-pulls-out-of-hemophilia-b-gene-therapy%2C-signaling-a-shift-in-strategy 2025-02-22 https://www.bio-focus.co.uk/pharma/moderna-reports-fourth-quarter-and-fiscal-year-2024-financial-results%2C-announces-strategic-initiatives 2025-02-19 https://www.bio-focus.co.uk/pharma/sanofi's-dupixent-receives-fda-priority-review-for-bullous-pemphigoid-treatment 2025-02-19 https://www.bio-focus.co.uk/pharma/novo-nordisk-unveils-promising-weight-loss-results-from-amycretin-clinical-trial 2025-01-26 https://www.bio-focus.co.uk/pharma/novartis'-intrathecal-onasemnogene-abeparvovec-phase-iii-study-meets-primary-endpoint-in-children-and-young-adults-with-sma 2025-01-05 https://www.bio-focus.co.uk/pharma/gsk%E2%80%99s-nucala-(mepolizumab)-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps 2025-01-05 https://www.bio-focus.co.uk/pharma/2025%3A-a-year-of-promise-in-pharma-and-biotech-%E2%80%94-key-trials-and-drug-candidates-to-watch 2025-01-05 https://www.bio-focus.co.uk/pharma/vertex-announces-fda-approval-of-alyftrek%E2%84%A2-for-cystic-fibrosis-treatment 2024-12-24 https://www.bio-focus.co.uk/pharma/merck-partners-with-hansoh-pharma-on-oral-glp-1-receptor-agonist-for-type-2-diabetes 2024-12-22 https://www.bio-focus.co.uk/pharma/astellas-and-avexis-collaborate-on-gene-therapy-for-spinal-muscular-atrophy-(sma) 2024-12-22 https://www.bio-focus.co.uk/pharma/roche%E2%80%99s-%241.5-billion-punt-on-poseida%3A-revolutionizing-car-t-therapy-for-the-masses 2024-11-29 https://www.bio-focus.co.uk/pharma/novo-nordisk%E2%80%99s-cagrisema-and-the-competitive-dynamics-in-the-obesity-drug-market 2024-11-09 https://www.bio-focus.co.uk/pharma/fda-approves-ngs-based-companion-diagnostic-for-targeted-therapy-in-grade-2-idh-mutant-glioma-patients 2024-11-05 https://www.bio-focus.co.uk/pharma/shockwave-medical-demonstrates-intravascular-lithotripsy's-efficacy-for-lower-limb-lesions-at-viva-2024 2024-11-05 https://www.bio-focus.co.uk/pharma/-merck's-keytruda-receives-landmark-30th-eu-approval-for-two-new-indications-in-gynecologic-cancers 2024-10-27 https://www.bio-focus.co.uk/pharma/astrazeneca's-wainzua-recommended-for-eu-approval-as-new-therapy-for-severe-asthma 2024-10-27 https://www.bio-focus.co.uk/pharma/novartis-pays-china%E2%80%99s-baiyu-%2470m-upfront%2C-with-%241.1b-in-potential-milestones-for-small-molecule-cancer-candidate 2024-10-19 https://www.bio-focus.co.uk/pharma/roche's-new-breast-cancer-drug-itovebi-receives-fda-approval 2024-10-11 https://www.bio-focus.co.uk/pharma/stryker-acquires-nico-corporation 2024-09-23 https://www.bio-focus.co.uk/pharma/vicebio-secures-%24100-million-to-develop-innovative-respiratory-virus-vaccines- 2024-09-23 https://www.bio-focus.co.uk/pharma/researchers-secure-%C2%A33.9m-grant-to-explore-early-axonal-dysfunction-in-als-and-ftd 2024-08-09 https://www.bio-focus.co.uk/pharma/nhs-introduces-groundbreaking-gene-therapy-for-beta-thalassaemia 2024-08-14 https://www.bio-focus.co.uk/pharma/roche-accelerates-anti-obesity-drug-development-to-rival-eli-lilly-and-novo-nordisk 2024-08-01 https://www.bio-focus.co.uk/pharma/biovac-advances-africa's-vaccine-production-with-sanofi-and-eubiologics-partnerships- 2024-06-23 https://www.bio-focus.co.uk/pharma/nice-approves-vertex%E2%80%99s-modulator-drugs-for-cystic-fibrosis%3A-a-landmark-decision-for-the-nhs 2024-10-11 https://www.bio-focus.co.uk/pharma/bayer-pharmaceuticals-shakes-up-leadership-structure 2024-06-23 https://www.bio-focus.co.uk/pharma/fda-approves-the-first-prognostic-test-for-alzheimer%E2%80%99s-progression 2024-06-23 https://www.bio-focus.co.uk/pharma/chipscreen-newway-biosciences-initiates-phase-i-clinical-trial 2024-06-23